Dramatic Response to Convalescent Hyperimmune Plasma in Association With an Extended Course of Remdesivir in 4 B Cell-Depleted Non-Hodgkin Lymphoma Patients With SARS-Cov-2 Pneumonia After Rituximab Therapy
{{output}}
•Four B cell–depleted non-Hodgkin lymphoma (NHL) patients with SARS-CoV-2 pneumonia after rituximab therapy were initially treated with a 5-day remdesivir course and steroids. After transient virologic and clinical response, they all experienced early relaps... ...
